Bio-Rad Laboratories Inc. (NYSE:BIO) changes shares on Thursday trading session, with a change of 1.11% or $4.82 shares. The trading starts at $432.41 and closed at $432.42 throughout the day. The trading session low price was $425.43 and day high was $437.91 on Thursday, June 25. After the session, the Healthcare sector daily volume shifted to 0.21 million while its average volume is 305.83K. In other hand, the BIO market cap reached to $13.08B. While, its current target price is $437.24 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -3.73% and down -7.11% for month. Its quarterly performance was 28.13% above, while its half year performance is up 18.57%. BIO yearly performance stood at positive 44.29% and rise 18.16% for year-to-date. Current recommendation for Bio-Rad Laboratories Inc. is 1.30.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. BIO EPS (TTM) for 12-month is 52.17. EPS for this year is 456.30%, while for the next year its value is 9.07. Sales growth for the current quarter is 0.47 while its EPS Q/Q reached -21.00%. It has an EPS of 80.40% up for past five years and for the next five years will be up 17.80%.
Blackrock Inc., Vanguard Group, Inc. (The) and FMR, LLC are the top three holders in Bio-Rad Laboratories Inc. (BIO) stock. On Mar 30, 2020, Blackrock Inc. has 2.24 million shares which valued 783.58 million. On Mar 30, 2020, Vanguard Group, Inc. (The) owned 2.01 million shares which valued at 705.78 million. On Mar 30, 2020, FMR, LLC has a total of 0.73 million shares which valued at 256.34 million. In the end, FMR, LLC have 2.98% shares outstanding of Bio-Rad Laboratories Inc. (BIO) on Mar 30, 2020. The insider ownership moved to 1.70% and institutional holding shifted to 77.70%.
The company posted an EPS (TTM) of 52.17. According to the most recent quarter report on (Jun 2020), 3 analysts estimated an average EPS of 1.05, while 1.49 EPS posted a year ago period. Analyst Estimated EPS for BIO published in the report was 0.99-1.15 during the same period. Comparing with last year, the average estimated EPS was 1.49 which is lower than 1.91 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for BIO rise 14.38% for period of 200 days. SMA for 50 days was -3.38% which is showing red signal, while SMA-20 was -5.21%. The moving average value for Bio-Rad Laboratories Inc. (BIO) is 399.01 and 462.93 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in BIO stock. On Jun 01, Crowley Michael, EVP, GBL Commercial Operations, sold 1,500 trading shares at the cost of $485.40, which valued at 0.73 million. On May 13, HUTTON RONALD W, Vice President and Treasurer, sold 443 shares at the cost of $457.35, with total shares of 4,140. On Dec 04, ERNST TIMOTHY S, EVP, General Counsel & Sec, sold 1,906 shares at the cost of 370.11. After this transaction, ERNST TIMOTHY S total shares reached to 456 which valued at 0.71 million.